<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-22-01-2026-shutterstock_2314970855-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/PT-22-01-2026-shutterstock_2314970855-430x241.jpg"/>
                                    
                                    <figcaption>Myelofibrosis is a rare blood cancer causing bone marrow scarring, severe fatigue, anaemia, and enlarged spleen. Credit: Nemes Laszlo / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Opna Bio has received the US Food and Drug Administration’s (FDA) orphan drug designation for OPN-2853 (zavabresib), a bromodomain and extra-terminal motif (BET) small molecule inhibitor, to treat myelofibrosis.</p>



<p>The International Nonproprietary Names (INN) approved the generic name zavabresib for OPN-2853.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - GB-2064 in Myelofibrosis </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - INCB-57643 in Chronic Idiopathic Myelofibrosis... </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>Myelofibrosis is a rare blood cancer involving bone marrow scarring, resulting in anaemia, severe fatigue, ineffective production of blood cells, and an enlarged spleen. This disease affects 25,000 people in the US.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>The designation applies to investigational therapies that target rare diseases affecting less than 200,000 people in the US. Benefits include waiver of certain FDA fees, eligibility for seven years of market exclusivity upon approval, and tax credits on clinical trial costs.</p>



<p>In the ongoing Phase I PROMise study, which is led by Professor Adam Mead at the University of Oxford in partnership with Cancer Research UK, zavabresib is being studied as an add-on to ruxolitinib to treat patients with myelofibrosis who no longer respond to ruxolitinib.</p>



<p>Opna Bio’s pipeline includes OPN-6602, in Phase I trials for multiple myeloma; OPN-2853, in a combination Phase I study with ruxolitinib for myelofibrosis.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Opna Bio CEO Reinaldo Diaz said: “Receiving orphan drug designation for zavabresib in myelofibrosis is a significant regulatory milestone for Opna Bio and highlights the urgent need for new and effective treatment options for patients with this disease.</p>



<p>“Our investigator-sponsored clinical trial with zavabresib and ruxolitinib has shown impressive results to date, including durable spleen reduction in patients with advanced myelofibrosis.</p><div id="slot-two"></div>



<p>“We believe that selective BET inhibition alongside JAK inhibition offers a promising new therapeutic approach for patients with myelofibrosis. We are further encouraged by recent positive meetings with the FDA to continue to test zavabresib in additional clinical studies.”</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>

<p>Opna Bio has received FDA orphan drug designation for OPN-2853 (zavabresib), a BET small molecule inhibitor, to treat myelofibrosis, a rare blood cancer affecting 25,000 people in the US. This designation provides benefits such as waived FDA fees and seven years of market exclusivity upon approval. The ongoing Phase I PROMise study is evaluating zavabresib as an add-on to ruxolitinib for patients who no longer respond to the latter. CEO Reinaldo Diaz emphasized the significance of this milestone and the need for effective treatment options.</p>

Pharmaceutical Technology

iShares Global Healthcare

Mustang Bio

First Trust NYSE Arca Biotech Index Fd

Incyte

Ark Genomic Revolution ETF

Novartis AG

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

NOVARTIS AG

Health Care Select Sector SPDR

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

Bio-Rad Lab

BioAge Labs

SPDR S&P Biotech

Geratherm Medical AG

VG Health

Proshares Ultra Nasdaq Biotech

Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis